China's Zero-COVID Policy: Economic and Social Impacts of a Superior COVID-Containment Strategy

EXECUTIVE SUMMARY

The world has been battling the unprecedented public health crisis – novel coronavirus (COVID-19) pandemic – for more than two years. Since early January 2020, more than 532 million COVID-19 cases have been reported worldwide, while above 6.30 million people have died of the coronavirus disease¹.

Besides causing illness and death, COVID-19 has **significant multi-dimensional impacts** on the entire world, **including the following economic consequences**:

- Global GDP contracted 3.1% in 2020²;
- Foreign direct investment fell by more than 40% in 2020;
- Equity markets worldwide initially suffered sharp sell-offs;
- Heightened inflation induced by the associated supply shock has continued to be a major concern among many central banks worldwide because subsequent interest rate hikes would hamper the fragile global economic recovery and even lead to a recession;
- Global trade shrank as much as 9.5% in 2020. While the World Trade Organization is predicting
 global merchandise trade volume to grow 10.8% in 2021, it is merely enough to just offset the
 losses in 2020; and
- United Nations World Economic Situation and Prospects mid-2020 report estimated that the global economy would lose nearly US\$8.5 trillion in output during 2020 and 2021.

To tackle this highly deadly pandemic, various forms of medications have been developed. Around 12.05 billion doses of COVID-19 vaccine³ invented by Pfizer (PFE) in conjunction with BioNTech (BNTX), Moderna (MRNA), Johnson & Johnson (JNJ), Sinopharm (1099.HK), Sinovac and others have been administrated globally. Moreover, Pfizer (PFE) and Merck (MRK) have invented oral antiviral drugs to help prevent hospitalization and death. Furthermore, there are antibody therapies from Eli Lilly (LLY) and AstraZeneca (AZN), while China has approved its first COVID-19 antibody drug with 80% of efficacy in cutting hospitalization and death among high-risk people⁴.

Countries around the globe are using either one of the following strategies to deal with the COVID-19 pandemic: Zero-COVID and Living with COVID. Zero-COVID refers to the deployment of maximum subduing public health measures such as border closure, mass testing, mandatory quarantine, lockdown and the use of mitigation software for contact tracing and verifying one's vaccination status to stop community transmission of COVID-19 as soon as it is detected. The measures serve the common goal of getting back to zero new infection and resuming normal economic and social activities⁵. In contrast, Living with COVID represents an approach to treat COVID-19 as a normal infectious disease, similar to flu, and not as a public health crisis so that no particular protective measures are adopted.

¹ World Health Organization as of 11 June 2022

² IMF World Economic Outlook Update January 2022

³ World Health Organization as of 11 June 2022

⁴ https://www.tsinghua.edu.cn/en/info/1399/10869.htm#

⁵ Wikipedia



IMPORTANT DISCLOSURES

Cedrus Investments Ltd. ("Cedrus") does and seeks to do business with companies covered in research reports distributed by Cedrus. Investors should consider this report as only a single factor in making their investment decision.

For additional information, please send an e-mail to information@cedrusinvestments.com

For private circulation only. This report is prepared by Cedrus and is for informational purposes only and is not intended to be, nor should it be construed to be, an advertisement or an offer or a solicitation of an offer to buy or sell any securities. The information herein, or upon which opinions have been based, has been obtained from sources believed to be reliable, but no representations, express or implied, or guarantees, can be made as to their accuracy, timeliness or completeness. The information and opinions in this report are current as of the date of the report. We do not endeavor to update any changes to the information and opinions in this report. Unless otherwise stated, all views expressed herein (including estimates or forecasts) are solely those of our research department and subject to change without notice.

The information provided in this research report is not provided to and may not be used by any person or entity in any jurisdiction where the provision or use thereof would be contrary to applicable laws, rules or regulations of any governmental authority or regulatory or self-regulatory organization or clearing organization or where Cedrus is not authorized to provide such information.

This report does not take into account the specific investment objectives, financial situation, and the particular needs of any specific company that may receive it. Before acting on any information in this report, readers should consider whether it is suitable for their own particular circumstances and obtain professional advice related to their own investment needs and objectives. The value of securities mentioned in this report and income from them may go up or down, and investors may realize losses on any investments. Past performance is not a guide to future performance. Future terms are not guaranteed, and a loss of original capital may occur.

Neither the analysts responsible for this report nor any related household members are officers, directors, or advisory board members of any covered company. No one at a covered company is on the Board of Directors of Cedrus or its affiliates. The compensation for the analysts who prepare reports is determined exclusively by senior management. Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of Cedrus as a whole, of which investment banking, sales and trading are a part.

Cedrus does engage in investment banking. Cedrus does trade securities on a principal basis; however, Cedrus' research analysts are prohibited from owning securities they cover through Research Reports.

Copyright 2022 Cedrus Investments Ltd. All rights reserved. Any unauthorized use or disclosure prohibited.